According to GlobalData’s medical device pipeline database, 351 Transdermal Drug Delivery devices are in various stages of development globally. GlobalData’s report Transdermal drug delivery provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, 174 are in active development, while the remaining 183 are in an inactive stage of development. There are 101 products in the early stages of development, and the remaining 73 are in the late stages of development.
Drug delivery devices are used for administration of drug compounds in effective ways. Transdermal drug delivery (TDD) delivers medication through the skin. It is designed to allow the controlled release of medication into the bloodstream over a period of time, providing a more convenient and effective alternative to oral or injectable medication. It is typically composed of a reservoir containing the medication, a rate-controlling membrane, and an adhesive backing. When the system is applied to the skin, the medication diffuses through the rate-controlling membrane and into the bloodstream. The rate of release is controlled by the thickness and composition of the membrane.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Transdermal Drug Delivery pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Transdermal Drug Delivery devices. Overall, most of these Transdermal Drug Delivery pipeline devices are being developed by private entities.
Key players involved in the active development of Transdermal Drug Delivery include 4P Therapeutics, MEDRx, Nemaura Pharma, Sinsin Pharmaceutical, Icure Pharmaceutical, Starton Therapeutics, Medherant, NutriBand, Raphas and PharmaTher.
For a complete picture of the developmental pipeline for Transdermal Drug Delivery devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
